Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Wednesday: Intel Corporation (NASDAQ:INTC), AT&T Inc (NYSE:T), Cisco Systems, Inc (NASDAQ:CSCO), Dyax Corp (NASDAQ:DYAX)

• Intel Corporation (NASDAQ:INTC), with shares dwindled -1.22% is now trading at $30.89. The Stock is active as 11.38M shares changed hands versus its average volume of 36.43M shares.

• AT&T Inc (NYSE:T), with shares raised 0.49% is now trading at $32.81. The Stock is active as 8.42M shares changed hands versus its average volume of 24.59M shares.

• Cisco Systems, Inc (NASDAQ:CSCO) with shares declined -0.85% is now trading at $27.28. The Stock is active as 8.33M shares changed hands versus its average volume of 27.32M shares.

• Dyax Corp (NASDAQ:DYAX) with shares inclined 47.42% is now trading at $24.71, hitting new 52-week high of $26.11. The Stock is active as 13.39M shares changed hands versus its average volume of 1.22Mshares.

Latest NEWS regarding these Stocks are depicted underneath:

Dyax Corp. (NASDAQ:DYAX)

Dyax Corp. (DYAX), declared positive safety, pharmacokinetic, biomarker, and efficacy results from the Phase 1b clinical study of their investigational product, DX-2930. Discovered by Dyax, DX-2930 is a fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of hereditary angioedema (HAE) attacks.

The ongoing Phase 1b study is a multi-center, randomized, double-blind, placebo-controlled, multiple-ascending dose study designed to assess the safety, tolerability and pharmacokinetics of DX-2930 in HAE patients. An analysis of HAE attack rate was also conducted following a pre-specified statistical analysis plan. A total of 37 subjects were randomized to active drug or placebo in a 2:1 ratio across 4 dosing groups of 30, 100, 300, or 400 mg. Each subject received two doses of DX-2930 or placebo, separated by 14 days, and was followed for 15 weeks after the second dose.

DX-2930 was well tolerated at all dose levels. There were no deaths or subject discontinuations due to an adverse event. There were no serious adverse events in subjects treated with DX-2930 and no evidence of dose-limiting toxicity. There was no safety signal in treatment-emergent adverse events, clinical laboratory results, vital signs, or electrocardiograms. Subcutaneous injection was well tolerated.

Pharmacokinetic results demonstrated that DX-2930 has linear, dose-dependent exposure and a mean elimination half-life of about 14 days across all dose groups studied. Pharmacodynamic results from two different exploratory biomarker assays confirmed ex vivo plasma kallikrein inhibition in a dose- and time-dependent manner.

Dyax Corp., a biopharmaceutical corporation, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE.

Intel Corporation (NASDAQ:INTC)

Intel Corporation (INTC), has price to sale ratio of 2.65, however, price to book ratio is 2.67. With recent declined, the year-to-date (YTD) performance reflected a -16.1% decline. During the past month the stocks lose -7.25%, bringing three-month performance to -15.02% and six-month performance to -9.27%. The mean recommendation of analysts for this stock is 2.60. (where 1=Buy, 5=Sale).

Intel Corporation designs, manufactures, and sells integrated digital technology platforms worldwide. It operates through PC Client Group, Data Center Group, Internet of Things Group, Mobile and Communications Group, Software and Services, and All Other segments.

AT&T, Inc. (NYSE:T)

Today, AT&T, Inc. (T), declared that it has invested nearly $525 million in its best-in-class wireless and wired networks in Minnesota from 2011 through 2014, driving a wide range of upgrades to reliability, coverage, speed and performance for residents and business customers.

As part of its Project Velocity IP (VIP), an investment plan focused on network enhancement and expansion, AT&T in 2014 made 346 network upgrades in Minnesota, counting new cell sites and the addition of wireless and wired network capacity.

Notable Minnesota network enhancements in 2014 comprised of:

• A Distributed Antenna System (DAS) at TCF Bank Stadium at the University of Minnesota that quadrupled the coverage that was accessible in 2013.
• A DAS at the Mayo Clinic campus in Rochester.
• The rollout of High Definition Voice calls (Voice Over LTE) in the Minneapolis-St. Paul metropolitan area.

AT&T Inc. provides telecommunications services in the United States and internationally. The corporation operates through two segments, Wireless and Wireline.

Cisco Systems, Inc. (NASDAQ:CSCO)

Acuity Brands, Inc., one of the world’s leading providers of LED lighting solutions; Cisco Systems, Inc. (CSCO), the worldwide leader in IT; and Sensity Systems, the pioneer of Light Sensory Networks (LSN), will present an educational webinar, “Meeting the Presidential Challenge for Advanced Outdoor Lighting.” The webinar is designed to assist public sector organizations learn more about what it takes to get involved in the Presidential Challenge for Outdoor Lighting program, which was declared by the White House in January during the U.S. Conference of Mayors.

The Presidential Challenge webinar will define and introduce technologies that constitute the next generation of ‘advanced outdoor lighting.’ It will also describe how the Presidential Challenge program represents an important tangible step toward the creation of Smart Cities. Administered through the U.S. Department of Energy (DOE) Better Buildings program, the Presidential Challenge for Advanced Outdoor Lighting program has set a aim of upgrading 1.5 million streetlights nationwide to high-efficiency LEDs.

The event will be on April 8, 2015 at 11:00 a.m. PT (2:00 p.m. ET).

Cisco Systems, Inc. designs, manufactures, and sells Internet Protocol (IP) based networking products and services related to the communications and information technology industry worldwide.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.